Product pipeline      Malaria      Hepatitis C      Ebola and Marburg      Influenza      Respiratory Syncytial Virus      

Send by emailPrint this page
Ebola and Marburg

Medical need

Both Ebola and Marburg are acute viral disease fevers that often lead to severe illness and death. The infections normally affect multiple organs in the body and often cause bleeding. Transmission between humans generally requires close contact with blood or body fluids.

Most outbreaks have happened in equatorial Africa, but there is a risk of worldwide spreading by emigration, travelling and transportation of animals. It has been predicted that global warming will ease the spread of the viruses worldwide. 

No known effective therapies or treatments are currently available to combat these viruses.

Background and Rationale for T-cell based Ebola and Marburg vaccines

Vaccine development is crucially important to minimise the public health, social and economic impacts of natural filovirus outbreaks.

Our Ebola and Marburg vaccines, currently in preclinical development and in collaboration with the Vaccine Research Centre at the National Institutes of Health (NIH) are based on our proprietary adenoviral vectors, expressing Ebola antigens.